A Case of Lung Adenocarcinoma with an Organizing Pneumonia Appearance Which Demonstrated a Spontaneous Resolution After the Administration of Osimertinib
暂无分享,去创建一个
[1] J. Dowell,et al. Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature , 2019, In Vivo.
[2] J. Ahn,et al. Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[3] T. Betsuyaku,et al. EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with “Stop-And-Go” Osimertinib , 2017, Internal medicine.
[4] V. Papadimitrakopoulou. AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC. , 2016, Lung cancer management.
[5] R. Camidge,et al. Transient Asymptomatic Pulmonary Opacities Occurring during Osimertinib Treatment , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[6] M. Kusumoto,et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. , 2013, Respiratory investigation.